BMC Pharmacology

Table 2 Average rapamycin levels (ng/mL) ± standard errors in blood, brain, kidney, and tumor tissue.

From: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779

Rapamycin levels at 2–4 hours and 24 hours in blood, kidney, and brain
	2–4 Hours Post-Treatment			24 Hours Post-Treatment
	Rapamycin 8 mg/kg	CCI-779 8 mg/kg	P value*	Rapamycin 8 mg/kg	CCI-779 8 mg/kg	P value*
Number of Mice	4	4		4	4
Whole Blood	1650 ± 1715	872 ± 119	0.0003	86 ± 23	68 ± 42	NS
Brain Homogenates	295 ± 227	39 ± 14	NS (0.06)	107 ± 32	24 ± 16	0.003
Kidney Homogenates	1820 ± 264	751 ± 215	0.0003	190 ± 59	126 ± 43	NS
Rapamycin levels at 2–4 hours in tumors from the nude mouse experiment
	2–4 Hours Post-Treatment
	Early CCI-779	Early Rapamycin	Late Rapamycin	P value**
Number of Mice	4	4	4
Tumor Homogenates	395 ± 134	965 ± 665	1024 ± 393	NS

*Drug levels from rapamycin cohort compared with CCI-779 cohort for indicated tissue and time point, NS = not significant.
**Tumor drug levels from early CCI-779 cohort and late rapamycin cohort were compared with early rapamycin cohort, NS = not significant

Back to article page